pharma · Clostridium Difficile Infection · Ulcerative Colitis · MCRB
Seres Therapeutics
Seres Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker MCRB. Primary therapeutic focus areas include Clostridium Difficile Infection, Ulcerative Colitis, Metastatic Me
Cambridge, USA HQ
2010 Founded
129 Employees
Public company Type
MCRB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2010
- Employees
- 129
- Programs
- 8
- Drugs
- 7
- Patents
- 36
SER-109
Phase 3 · mab · Clostridium Difficile Infection
SER-109 for Clostridium Difficile Infection is a Phase 3 program (mab) at Seres Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code SERES-012
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Seres Therapeutics
- Phase
- Phase 3
- Modality
- mab
- Indication
- Clostridium Difficile Infection
- Status
- completed
- Trials
- 1